

RESEARCH OUTPUTS / RÉSULTATS DE RECHERCHE

Cardiovascular effect of BCR-ABL TKIs: a meta-analysis and systematic review of arterial and venous occlusive events

Haguet, Hélène; Mullier, François; Chatelain, Christian; Graux, Carlos; Dogné, Jean-Michel; Douxfils, Jonathan

Publication date:
2016

[Link to publication](#)

Citation for published version (HARVARD):

Haguet, H, Mullier, F, Chatelain, C, Graux, C, Dogné, J-M & Douxfils, J 2016, 'Cardiovascular effect of BCR-ABL TKIs: a meta-analysis and systematic review of arterial and venous occlusive events', 62nd Annual SSC Meeting of the International Society of Thrombosis and Hemostasis, Montpellier, France, 25/05/16 - 28/05/16.

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

1. Giles FJ, Mauro MJ, Hong F, Ortmann CE, McNeill C, Woodman RC, et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. *Leukemia*. 2013;27(6):1310-5.
2. Quintás-Cardama A, Kantarjian H, Cortes J. Nilotinib-associated vascular events. *Clinical lymphoma, myeloma & leukemia*. 2012;12(5):337-40.
3. Douxfils J, Haguet H, Mullier F, Chatelain C, Graux C, Dogné JM. Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival: A Systematic Review and Meta-analysis. *JAMA oncology*. 2016.